DoW Neurofibromatosis Exploration-Hypothesis Development Award | HT942526NFRPEHDA

Opportunity Information: Apply for HT942526NFRPEHDA

The FY26 Neurofibromatosis Research Program (NFRP) Exploration-Hypothesis Development Award (EHDA) is a discretionary federal grant opportunity designed to help researchers test fresh, early-stage ideas in neurofibromatosis (NF). The focus is on getting bold, high-risk concepts off the ground so they can mature into stronger, future research directions. Projects funded through this mechanism are expected to be exploratory in nature, but still anchored by a clearly stated and testable hypothesis, supported by a solid scientific rationale and a thoughtful study design. In practical terms, the award is meant for investigators who want to probe an emerging idea, generate initial evidence, and establish feasibility or foundational insight that can support later, larger efforts.

A central priority of this award is innovation. The program is explicitly looking for work that goes beyond incremental advances, such as proposing a new way to understand NF biology, challenging a commonly accepted model, applying a tool or method in an unconventional way, or reframing a stubborn problem from a different angle. The intent is to encourage creative research that might feel too risky for more traditional funding sources, but that could have outsized impact if it succeeds. This makes the EHDA a strong fit for studies that aim to open up new lines of inquiry, create new conceptual frameworks, or generate novel hypotheses that could reshape how NF is studied or treated.

The opportunity also lowers the barrier to entry regarding prior results. Preliminary and/or published data are encouraged, but they are not required. That detail is important because it signals the program is willing to support well-justified ideas even if the applicant does not yet have extensive proof-of-concept data in hand. At the same time, the proposal still needs to present a coherent hypothesis and a credible plan for testing it, meaning reviewers will likely be looking for strong logic, sound methods, and clear outcomes that would meaningfully inform next steps in the field.

Administratively, this opportunity is offered by the Defense Health Agency Contracting Activity (DHACA) under the Department of Defense research funding ecosystem. The funding instrument type is a grant, and it falls under the Science and Technology and other Research and Development activity category, with CFDA number 12.420. Eligibility is listed as unrestricted, which generally indicates a broad range of applicants may apply, rather than limiting the competition to specific organization types. The opportunity is identified by the funding opportunity number HT942526NFRPEHDA, was created on June 25, 2026, and has an original closing date of September 22, 2026. The program anticipates making about 8 awards. An award ceiling is not specified in the provided listing, so prospective applicants would typically need to consult the full announcement package for budget limits, period of performance details, allowable costs, and any topic-specific constraints.

Overall, the EHDA is positioned as a launchpad for NF research ideas that are ambitious and potentially transformative, where the main deliverable is a strong early demonstration that a novel hypothesis is worth pursuing. Successful projects should leave the field with a clearer direction for follow-on studies, whether that means new mechanistic insight, a validated approach, a feasible model system, an enabling dataset, or compelling evidence that a new concept deserves larger-scale investment.

• The Defense Health Agency Contracting Activity - DHACA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoW Neurofibromatosis Exploration-Hypothesis Development Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on 2026-06-25.
• Applicants must submit their applications by 2026-09-22. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 8 candidate(s).
• Eligible applicants include: Unrestricted.

Apply for HT942526NFRPEHDA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: